Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

December 31, 2027

Conditions

AML With Gene Mutations

Interventions

DRUG

ZE46-0134

oral capsules QD

Trial Locations (1)

RECRUITING

Linear Clinical Research Ltd, Perth